Maximal exercise testing of men with prostate cancer being treated with androgen deprivation therapy

Medicine and Science in Sports and Exercise

Volumn 46, Issue 12, 2014, Pages 2210-2215

  Wall, Bradley A ^a,b   Galvão, Daniel A ^b   Fatehee, Naeem ^b   Taaffe, Dennis R ^b,c,d   Spry, Nigel ^b,e,f   Joseph, David ^b,e,f   Newton, Robert U ^b  

^a MURDOCH UNIVERSITY   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cardiopulmonary testing; Cardiorespiratory capacity; Oncology; Screening

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ADVERSE EFFECTS; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART RATE; HUMAN; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART RATE; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84916598381     PISSN: 01959131     EISSN: 15300315     Source Type: Journal    
DOI: 10.1249/MSS.0000000000000353     Document Type: Article

References (40)

1. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1): 14-25.
2. Alibhai SM, Breunis H, Timilshina N, et al. Impact of androgenpeprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol. 2010;28(34): 5038-45.
3. American Thoracic Society, American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2): 211-77.
4. Balady GJ, Chaitman B, Driscoll D, et al. Recommendations for cardiovascular screening, staffing, and emergency policies at health/fitness facilities. Circulation. 1998;97(22): 2283-93.
5. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3): 581-8.
6. Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate cancer patients-A systematic review of randomized controlled trials. Support Care Cancer. 2012;20(2): 221-33.
7. Bruce RA. Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation. Ann Clin Res. 1971;3(6): 323-32.
8. Chen AC, Petrylak DP. Complications of androgen-deprivation therapy in men with prostate cancer. Curr Urol Rep. 2005;6(3): 210-6.
9. Cohn JN. Exercise tolerance as a guide to therapeutic efficacy for heart failure: The potential for angiotensin receptor blockers. Circulation. 1999;100(22): 2208-9.
10. Courneya KS, Friedenreich CM. Relationship between exercise pattern across the cancer experience and current quality of life in colorectal cancer survivors. J Altern Complement Med. 2007;3(3): 215-26.
11. Daida H, Allison TG, Squires RW, Miller TD, Gau GT. Peak exercise blood pressure stratified by age and gender in apparently healthy subjects. Mayo Clin Proc. 1996;71(5): 445-52.
12. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2): 195-201.
13. Fletcher GF, Balady G, Froelicher VF, Hartley LH, Haskell WL, Pollock ML. Exercise standards. A statement for healthcare professionals from the American Heart Association. Writing Group. Circulation. 1995;91(2): 580-615.
14. Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: A statement for healthcare professionals from the American Heart Association. Circulation. 2001;104(14): 1694-740.
15. Fox SM 3rd, Naughton JP, Haskell WL. Physical activity and the prevention of coronary heart disease. Ann Clin Res. 1971;3(6): 404-32.
16. Galvão DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102(1): 44-7.
17. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: A randomized controlled trial. J Clin Oncol. 2010;28(2): 340-7.
18. Galvão DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 2009;12(2): 198-203.
19. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA guidelines for exercise testing: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Circulation. 1997;96: 345-54.
20. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12): 6410-7.
21. Irwin ML, Crumley D, McTiernan A, et al. Physical activity levels before and after a diagnosis of breast carcinoma: The Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer. 2003;97(7): 1746-57.
22. Jones LW, Alfano CM. Exercise-oncology research: Past, present, and future. Acta Oncol. 2013;52(2): 195-215.
23. Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol. 2009;10(6): 598-605.
24. Jones LW, Eves ND, Mackey JR, et al. Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer. 2007;55(2): 225-32.
25. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer. J Natl Cancer Inst. 2009;102(1): 39-46.
26. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60(3): 194-201.
27. Newton R, Taaffe D, Spry N, et al. A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer. BMC Cancer. 2009;9(1): 210.
28. Quon H, Loblaw DA. Androgen deprivation therapy for prostate cancer-review of indications in 2010. Curr Oncol. 2010;17(2 Suppl): S38-44.
29. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7): 1493-500.
30. Segal RJ, Reid RD, Courneya KS, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27(3): 344-51.
31. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166: 465-71.
32. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8): 1615-24.
33. Sharma K, Kohli P, Gulati M. An update on exercise stress testing. Curr Problem Cardiol. 2012;37(5): 177-202.
34. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9): 4261-7.
35. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2): 599-603.
36. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91(4): 1305-8.
37. Steins Bisschop CN, Velthuis MJ, Wittink H, et al. Cardiopulmonary exercise testing in cancer rehabilitation: A systematic review. Sports Med. 2012;42(5): 367-79.
38. Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart rate revisited. J Am Coll Cardiol. 2001;37(1): 153-6.
39. Thompson WR, Gordon NF, Pescatello LS. ACSM's Guidelines for Exercise Testing and Prescription. Baltimore (MD): Lippincott Williams & Wilkins; 2010.
40. Yancik R. Population Aging and Cancer: A Cross-National Concern. Cancer J. 2005;11(6): 437-41.